Emergent BioSolutions, Inc. (NYSE:EBS) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Emergent BioSolutions, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 38.1% to $0.29 in the quarter versus EPS of $0.21 in the year-earlier quarter.
Revenue: Rose 17.08% to $82.4 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Emergent BioSolutions, Inc. reported adjusted EPS income of $0.29 per share. By that measure, the company beat the mean analyst estimate of $0.21. It beat the average revenue estimate of $75.73 million.
Quoting Management: Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions, stated, “We are very pleased with our performance for the second quarter and year-to-date. We achieved strong financial results and significantly advanced our operational objectives, including closing on the Healthcare Protective Products Division of Bracco Diagnostics, Inc., securing German approval of BioThrax® with a three-dose primary series and triennial boosters, and continuing to progress our biodefense and biosciences development programs. We are well positioned to continue to deliver financial results in accordance with our forecast and to execute on our growth plan.”
Key Stats (on next page)…